OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females

• Status: Completed
• Trial end date: 2016-12-22
• Target enrollment: 0
• Participant gender: Female

Summary

This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared with placebo as treatment for major depressive disorder (MDD) in adult females.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A; incobotulinumtoxinA; onabotulinumtoxinA

Criteria

Inclusion Criteria:

• Moderate to severe major depressive disorder

Exclusion Criteria:

• Prior treatment with botulinum toxin of any serotype for any reason

• Use of antidepressant medication for depression within 2 weeks of study

• Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis